Drug-drug Interaction Study of XZP-3621 Tablet

Phase 1 Unknown 72 enrolled Xuanzhu Biopharmaceutical Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, single center, 2 period, one sequence study to investigate the potential drug drug interaction between itraconazole or rifampin or esomeprazole and XZP-3621 tablet.

Timeline

Start: 2022-11-15
Primary completion: 2023-04-05
Completion: 2023-08-02

Publications

Fang L, Jiang X, Song K, Shi P, Wang L, Xu L, Duan X, Liu F, Sun F, Ban R, Ma Y, Wang C, Cao Y. Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib). Cancer Chemother Pharmacol. 2025 Dec 5;95(1):122. doi: 10.1007/s00280-025-04837-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dirozalkib	Unknown	500 mg	Oral
Subject	Esomeprazole	Small molecule	40 mg	Oral
Subject	Itraconazole	Small molecule	—	Oral
Subject	Rifampin	Small molecule	—	—

Indications

No indication recorded.